Loading…
Biomerica Inc
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
None of the investors we track reported a position in BMRA.
▼ -93.7% over 5Y.
today you would have $64.44▼ -93.6%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 16 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $2.32 | $2.52 | $2.40 | $10.00 | $26.80 | $31.12 | $39.84 | $24.16 | $13.60 | $29.92 | $18.40 | $10.32 | $7.12 | $6.24 | $6.72 | $3.84 | |
| P/E | 11.1x |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| DRMADermata Therapeutics, Inc. | $1.34 | — | 1.5x | — | -183.89% | $6.64M |
| VNRXVolitionrx Ltd | $0.45 | — | — | — | — | $6.48M |
| CLGNCollPlant Biotechnologies Ltd | $0.36 | — | 1.1x | — | -151.99% | $6.77M |
| ACONAclarion, Inc. | $2.40 |
Biomerica, Inc., a biomedical technology company, engages in developing, patenting, manufacturing, and marketing diagnostic and therapeutic products for the detection and treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications, as well as to measure the levels of specific bacteria, hormones, antibodies, antigens, and other substances which may exist in the human body, stools, or blood in extremely small concentrations. It sells its products for treating gastrointestinal diseases and food intolerances, as well as various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also involved in the development of InFoods IBS, that uses a simple blood sample to identify patient-specific foods which may alleviate irritable bowel syndrome symptoms; and hp+detect, a H. Pylori diagnostic test that indicates if a patient is infected with the Helicobacter pylori bacteria. The company has strategic partnerships with Phoenix Airmid Biomedical and CanAlt Health Labs for launching the inFoods platform in Canada. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.
Company description provided by Yahoo Finance.
| — |
| — |
| — |
| — |
| — |
| — |
| — |
| — |
| — |
| — |
| — |
| — |
| — |
| 11.1x |
| 10.5x |
| 24.0x |
| P/S | 2.4x | 2.4x | 1.4x | 0.9x | 3.9x | 2.4x | 6.8x | 8.7x | 5.7x | 2.7x | 5.5x | 3.7x | 2.0x | 1.3x | 0.9x | 1.0x | 0.7x |
| P/B | 2.7x | 4.0x | 1.8x | 0.8x | 1.8x | 5.4x | 5.3x | 4.1x | 7.4x | 3.5x | 7.1x | 3.6x | 1.7x | 1.1x | 1.0x | 1.2x | 0.8x |
| EPS | -$1.30 | -$2.16 | -$2.84 | -$4.00 | -$2.88 | -$4.96 | -$2.08 | -$2.08 | -$1.36 | -$0.88 | -$1.60 | -$0.32 | -$0.24 | $0.56 | $0.64 | $0.16 |
| Profit margin | -27.76% | -84.77% | -93.64% | -110.40% | -133.73% | -24.01% | -103.43% | -40.00% | -46.01% | -26.34% | -15.69% | -29.18% | -6.68% | -4.21% | 8.30% | 9.02% | 3.21% |
| ROE | -31.31% | -143.54% | -121.14% | -90.70% | -60.90% | -54.43% | -80.69% | -18.84% | -60.11% | -33.89% | -20.24% | -28.73% | -5.92% | -3.65% | 9.20% | 11.02% | 3.64% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
| — |
| 0.3x |
| — |
| -58.97% |
| $6.92M |
| HCWBHCW Biologics Inc. | $3.43 | — | 0.7x | — | -151.36% | $6.3M |
| SNOASonoma Pharmaceuticals, Inc. | $1.31 | — | 0.8x | — | -42.52% | $6.27M |